Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced-stage ovarian cancer.
Adult
Aged
Aged, 80 and over
Argon Plasma Coagulation
/ instrumentation
Cytoreduction Surgical Procedures
/ methods
Female
Follow-Up Studies
Humans
Middle Aged
Neoadjuvant Therapy
/ methods
Neoplasm Staging
Ovarian Neoplasms
/ drug therapy
Retrospective Studies
Survival Rate
Treatment Outcome
Young Adult
PlasmaJet™
argon plasma
cytoreductive surgery
debulking
ovarian cancer
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
23
07
2020
revised:
26
11
2020
accepted:
03
01
2021
pubmed:
27
1
2021
medline:
11
3
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
The aim was to evaluate the effectiveness and safety of PlasmaJet™ in cytoreductive surgery in patients with advanced-stage ovarian cancer. All patients between September 2013 and January 2018 undergoing surgical cytoreduction for advanced-stage ovarian cancer with the help of PlasmaJet™ were identified and analyzed retrospectively. Eighty-seven patients diagnosed with advanced-stage ovarian cancer underwent surgery with PlasmaJet™. Primary debulking surgery was performed in 15 cases. Fifty-seven patients underwent interval debulking after neoadjuvant chemotherapy. Secondary and tertiary debulking was done in, respectively, 11 and three patients, and one patient underwent quaternary debulking using PlasmaJet™. In all 87 patients but one, complete resection of all macroscopic disease was obtained. PlasmaJet™ was used to remove carcinomatosis on the peritoneum, bowel serosa, intestinal mesentery, and lesions in the upper abdomen (diaphragm and liver surface). No damage to the bladder or ureter was noted in relation to the use of PlasmaJet™. Three patients developed a bowel leakage postoperatively. In one of these patients, PlasmaJet™ was used to treat tumoral implants in the affected region. Our series suggests that the use of PlasmaJet™ is efficient and safe in obtaining complete resection of all macroscopic tumoral lesions in advanced-stage ovarian cancer.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1109-1114Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Sant M, Chirlaque Lopez MD, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2191-2205.
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296.
Vergote IB, Van Nieuwenhuysen E, Vanderstichele A. How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma. J Clin Oncol. 2016;34(32):3827-3828.
Meyer LA, Cronin AM, Sun CC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34(32):3854-3863.
Madhuri TK, Papatheodorou D, Tailor A, Sutton C, Butler-Manuel S. First clinical experience of argon neutral plasma energy in gynaecological surgery in the UK. Gynecol Surg. 2010;7:423-425.
Renaud MC, Sebastianelli A. Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer. J Obstet Gynaecol Can. 2013;35(1):49-52.
Panuccio E, Leunen K, Van Nieuwenhuysen E, Neven P, Lambrechts S, Vergote I. Use of PlasmaJet for peritoneal carcinomatosis in ovarian cancer. Int J Gynecol Cancer. 2016;26(8):1521-1524.
Deb S, Sahu B, Deen S, Newman C, Powell M. Comparison of tissue effects quantified histologically between PlasmaJet coagulator and Helica thermal coagulator. Arch Gynecol Obstet. 2012;286(2):399-402.
Tanner J, Dun E, Sonoda Y. A comparison of thermal plasma energy versus argon beam coagulator-induced intestinal injury after vaporization in a Porcine model. Int J Gynecol Cancer. 2017;27(1):177-182.
Bourdel N, Chauvet P, Roman H, et al. Comparison between resection, bipolar coagulation and Plasmajet®: a preliminary animal study. Eur J Obstet Gynecol Reprod Biol. 2017;211:127-133.
Butler-Manuel SA, Lippiatt J, Madhuri TK. Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet™). Gynecol Oncol. 2014;135(3):622-623.
Vitale SG, Marilli I, Lodato M, Tropea A, Cianci A. The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. Updates Surg. 2013;65(4):265-270.
Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. CD005343
Giorda G, Gadducci A, Lucia E, et al. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. J Ovarian Res. 2014;7:72.
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;2011(8):CD007565.
Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2:CD008765.
Du Bois A, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOPIII/ENGOTov20. J Clin Oncol. 2017;15(Suppl):5501.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213.
Slankamenac K, Graf R, Puhan MA, Clavien PA. Perception of surgical complications among patients, nurses and physicians: a prospective cross-sectional survey. Patient Saf Surg. 2011;22;5(1):30.
Grimm C, Harter P, Alesina PF, et al. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol. 2017;146(3):498-503.
Tozzi R, Casarin J, Baysal A, et al. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patients with stage IIIC-IV ovarian cancer. J Gynecol Oncol. 2019;30(2):e25.
Estes JM, Leath CA, Straughn JM, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203(4):527-532.
Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083-1090.
Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103(3):977-984.
Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-257.
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953.
Prodromidou A, Pandraklakis A, Iavazzo C. The emerging role of neutral argon plasma (PlasmaJet) in the treatment of advanced stage ovarian cancer: a systematic review. Surg Innov. 2020;27(3):299-306.
Cordeiro Vidal G, Babin G, Querleu D, Guyon F. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer. Gynecol Oncol. 2017;144(1):223-224.
Nieuwenhuyzen-de Boer GM, Hofhuis W, Reesink-Peters N, et al. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands. BMC Cancer. 2019;19(1):58.